RESPIRATORY SYNCYTIAL VIRUS (RSV) Clinical Trial
— PICASSOOfficial title:
A PHASE 1, OPEN-LABEL, AGE-DESCENDING, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE (RSVpreF) IN CHILDREN 2 TO <18 YEARS OF AGE
Verified date | April 2024 |
Source | Pfizer |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to learn about the safety and immune activity of the vaccine (called RSVpreF) in children 2 to <18 years of age. This study will identify the dose level to be used in Phase 2/3 trials in this age cohort. All participants will receive one injection of RSVpreF. This study has four study visits, two in-clinic and two telehealth visits. Blood samples will be collected for testing. This study is about 6 months long for each participant and will be conducted in the United States.
Status | Completed |
Enrollment | 128 |
Est. completion date | February 29, 2024 |
Est. primary completion date | February 29, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 2 Years to 17 Years |
Eligibility | Inclusion Criteria: 1. Participants 2 to <18 years of age at enrollment 2. Participants 2 to <18 years of age should either be healthy or be considered by the investigator to be at high risk of RSV disease based on the presence of 1 of the following chronic medical conditions: - Cystic fibrosis - Medically treated asthma - Other chronic respiratory diseases and malformations of the lung - Down syndrome - Neuromuscular disease - Cerebral palsy - Hemodynamically significant or symptomatic congenital heart disease 3. All participants 2 to <5 years of age must be seropositive for RSV as confirmed by serology. 4. Participants' parent(s)/legal guardian(s) and participants, as age appropriate, who are willing and able to comply with all scheduled visits, investigational plan, laboratory tests, and other study procedures, including collection of nasal swabs by participants' parent(s)/legal guardian(s) and by study staff when indicated. 5. The participant's parent(s)/legal guardian is capable of giving signed informed consent as described in the protocol. Depending on the age of the participant and according to local requirements, participants will also be asked to provide assent as appropriate (verbal or written). Exclusion Criteria: 1. Immunocompromised individuals associated with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination. 2. Individuals with a history of autoimmune disease or an active autoimmune disease requiring therapeutic intervention, including but not limited to systemic lupus erythematosus. Note: Stable type 1 diabetes and hypothyroidism are permitted. 3. Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study. 4. History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s). 5. Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection. 6. Individuals with a history of epilepsy or other seizure disorders, or a history of seizures and/or other neurological complications following vaccination. 7. Previous vaccination with any licensed or investigational RSV vaccine or planned receipt during study participation. Children who may have been exposed to investigational RSV vaccines through maternal immunization will be permitted. 8. Receipt of investigational or approved monoclonal antibodies against RSV within 6 months before study intervention administration, or planned receipt throughout the study. 9. Receipt of blood/plasma products or immunoglobulins within 28 days before study intervention administration, or planned receipt throughout the study. 10. Receipt of chronic systemic treatment with known immunosuppressant medications (including cytotoxic agents or systemic corticosteroids), or radiotherapy, within 60 days before study intervention administration, or planned receipt throughout the study. Note: Systemic corticosteroids are defined as those administered for =14 days at a dose of =20 mg/day of prednisone or equivalent (eg, for cancer or an autoimmune disease). Inhaled/nebulized, intra-articular, intrabursal, or topical (skin, eyes, or ears) corticosteroids are permitted. 11. Participation in other studies involving study intervention within 28 days prior to study entry and/or for the duration of study participation. 12. Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members. |
Country | Name | City | State |
---|---|---|---|
United States | ARC Clinical Research at Four Points | Austin | Texas |
United States | Velocity Clinical Research, Austin | Austin | Texas |
United States | University of Alabama at Birmingham - School of Medicine | Birmingham | Alabama |
United States | Velocity Clinical Research, Austin | Cedar Park | Texas |
United States | Cincinnati Children's Hospital Medical Center | Cincinnati | Ohio |
United States | Duke Vaccine And Trials Unit | Durham | North Carolina |
United States | Velocity Clinical Research, Providence | East Greenwich | Rhode Island |
United States | Velocity Clinical Research, Metairie | Metairie | Louisiana |
United States | Bio-Medical Research LLC | Miami | Florida |
United States | Velocity Clinical Research, Omaha | Omaha | Nebraska |
United States | Stanford University Medical Center | Palo Alto | California |
United States | Rochester Clinical Research, LLC | Rochester | New York |
United States | Peninsula Research Associates | Rolling Hills Estates | California |
United States | Seattle Children's - Building Cure | Seattle | Washington |
United States | Seattle Children's Hospital | Seattle | Washington |
United States | Velocity Clinical Research, Sioux City | Sioux City | Iowa |
United States | Senders Pediatrics | South Euclid | Ohio |
United States | Velocity Clinical Research, Salt Lake City | West Jordan | Utah |
Lead Sponsor | Collaborator |
---|---|
Pfizer |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Primary Safety - The proportion of participants reporting local reactions | Local reactions include pain at injection site, redness and swelling reported on e-diaries. | Within 7 days following study administration intervention | |
Primary | Primary Safety - The proportion of participants reporting systemic reactions | Systemic reactions: fever, fatigue/tiredness, headache, muscle pain, joint pain, vomiting, diarrhea reported on e-diaries. | Within 7 days following study administration intervention | |
Primary | Primary Safety - The proportion of participants reporting Adverse Events (AEs) | An AE is any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. AEs include both serious and non-serious adverse events. | Through 1 month following study administration intervention | |
Primary | Primary Safety - The proportion of participants reporting Serious Adverse Events (SAEs) | SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. | Throughout the study duration (approximately 6 months) | |
Primary | Primary Safety - The proportion of participants reporting Newly Diagnosed Chronic Medical Conditions (NDCMCs) | An NDCMC is defined as a disease or medical condition, not previously identified, that is expected to be persistent or otherwise long-lasting in its effects. | Throughout the study duration (approximately 6 months) | |
Secondary | Secondary Immunogenicity - GMT of NTs for RSV A and RSV B | RSV A and RSV B neutralizing titers (NT), expressed as Geometric Mean Titers (GMTs). | At each blood sampling visit (Day 1 before vaccination and 1-month after vaccination) | |
Secondary | Secondary Immunogenicity - GMFR of NTs for RSV A and RSV B | RSV A and RSV B neutralizing titers (NT), expressed as Geometric Mean Fold Rise (GMFR). | At each blood sampling visit (Day 1 before vaccination and 1-month after vaccination) | |
Secondary | Secondary Immunogenicity - Median frequencies of RSV F antigen-specific CD4+ T cells expressing IFN gamma | As measured at the central laboratory, RSV F antigen-specific CD4+ T cells secreting IFN gamma | At each blood sampling visit (Day 1 before vaccination and 1-month after vaccination) | |
Secondary | Secondary Immunogenicity - Median frequencies of RSV F antigen-specific CD4+ T cells expressing IL-4 | As measured at the central laboratory, RSV F antigen-specific CD4+ T cells secreting IL-4 | At each blood sampling visit (Day 1 before vaccination and 1-month after vaccination) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02593071 -
Safety and Immunogenicity of the RSV-F Vaccine in Older Adults Previously Treated With the Same Vaccine or Placebo in the Prior Year.
|
Phase 2 | |
Completed |
NCT02266628 -
Placebo- Controlled Study to Evaluate the Safety and Immunogenicity of the RSV-F Vaccine in Elderly Adults
|
Phase 2 | |
Completed |
NCT02282982 -
Observational Program to Assess Respiratory Syncytial Virus (RSV) Hospitalization Rate in Population of Children at High-risk of Serious RSV Illness Who Received Palivizumab Immunoprophylaxis
|
N/A | |
Completed |
NCT01704365 -
RSV-F Vaccine Dose Ranging Study in Young Women
|
Phase 2 | |
Completed |
NCT01709019 -
RSV-F Vaccine and Influenza Vaccine Co-Administration Study in the Elderly
|
Phase 1 | |
Recruiting |
NCT06185647 -
Evaluation in Practice of the Impact of NIrsevimab on EmeRgency Use for BRONCHIOlitis
|
||
Recruiting |
NCT04925310 -
Infection With Respiratory Syncytial Virus in Infants
|
||
Completed |
NCT02968173 -
A Study to Assess the Safety and Effectiveness of Palivizumab Administered to Children at High Risk of Severe Respiratory Syncytial Virus (RSV) Infection in the Russian Federation and the Republic of Belarus
|
Phase 3 | |
Active, not recruiting |
NCT06077149 -
Immunogenicity of RSV Vaccines in Residents of Long-Term Care Facilities (LTCF)
|
Phase 4 | |
Completed |
NCT02608502 -
A Study to Evaluate the Efficacy of an RSV F Vaccine in Older Adults
|
Phase 3 | |
Recruiting |
NCT05047549 -
Community-based RSV Surveillance in Infant Mortality: Minimally Invasive Tissue Sampling Study in Karachi, Pakistan
|
||
Terminated |
NCT04225897 -
A Study to Learn About the Effects of Sisunatovir in Infants With Respiratory Syncytial Virus Lower Respiratory Tract Infection.
|
Phase 2 | |
Recruiting |
NCT06216093 -
Phase I, First-In Human Study to Evaluate Safety and Tolerability of EuRSV in Healthy Adults Aged Between 19 Years and 80 Years
|
Phase 1 | |
Not yet recruiting |
NCT06392451 -
LIAISON NES Influenza (FLU) A/B, Respiratory Syncytial Virus (RSV), & Coronavirus Disease 2019 (COVID-19) in Symptomatic Patients in Australia
|
N/A | |
Completed |
NCT04927793 -
Absorption, Metabolism, and Excretion (AME) Study of [14C]EDP-938 in Healthy Male Subjects
|
Phase 1 | |
Active, not recruiting |
NCT05443607 -
Transplacental Transmission of RSV (TTRSV)
|
||
Recruiting |
NCT04896853 -
Treatment of Respiratory Complications Associated With COVID19,Influenza ,Metapneumovirus,RSV Infection Using ProTrans®
|
Phase 1 | |
Completed |
NCT03916185 -
Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age
|
Phase 1/Phase 2 | |
Completed |
NCT05842967 -
A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Adults at High Risk of Severe RSV Disease
|
Phase 3 | |
Recruiting |
NCT04909021 -
Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seronegative Children 6-36 Months
|
Phase 1 |